New Data Shows Biopharma Sector Successfully Decouples Industrial Output from Carbon Footprint
New Data Shows Biopharma Sector Successfully Decouples Industrial Output from Carbon Footprint
- Pharmaceutical exports jumped 29%, electricity-related CO2 emissions plummeted by 30.5%
- Over €150 million has been poured into cleaner technologies in the last four years to get ahead of upcoming EU environmental directives.
BioPharmaChem Ireland (BPCI), the Ibec group representing the biopharmaceutical and chemical sectors, today published its Sustainability and Responsible Care Report 2026 showing an historic milestone for the industry by achieving significant increases in industrial productivity and high-value exports while successfully holding, and in many cases decreasing, its core environmental impact.
Despite a 29% surge in pharmaceutical exports in 2024—and a 5.2% increase in employment over the three-year ) reporting period (2022 to 2024 inclusive), the sector has driven remarkable environmental improvements. Key achievements include a 30.5% reduction in electricity-related CO2 emissions, a 3% drop in total energy consumption, and a 23% reduction in Volatile Organic Compounds (VOCs).
Speaking at the launch, Sinead Keogh, Director of BioPharmaChem Ireland, said:
"The 2026 Responsible Care report tells a powerful story of decoupling. Our members are navigating an unprecedented convergence of legislative reforms, from the recast Industrial Emissions Directive to stringent new EU water-protection measures. The fact that the sector has significantly reduced its energy consumption and emissions while growing exports by 29% to €99.9 billion in 2024 proves that high-value manufacturing and rigorous environmental stewardship can advance together. Ireland is actively cementing its position as a global leader in sustainable biopharmaceutical manufacturing."
The report notes that the sector has invested over €150 million in the last four years in cleaner technologies and upgraded site infrastructure. This proactive investment is effectively pre-empting the substantial decarbonisation requirements of the new Industrial Emissions Directive (IED 2.0). The industry has also made significant strides in circular economy practices, achieving a substantial 37% reduction in non-hazardous waste generation and hitting a record 88% recycling rate across member sites.
Brian Killen, Digital Transformation and Global Operational Excellence lead, MSD, added: "Through collective action and a shared commitment to sustainability, we aim to create a future where Ireland stands as a beacon of excellence in the sustainable manufacture and supply of biopharmaceuticals, pharmaceuticals, and chemicals. By integrating advanced monitoring and embracing continuous process optimisation, our facilities are not just adapting to a changing regulatory landscape; they are setting the standard for the next generation of life sciences manufacturing."
Water stewardship remains a critical strategic focus for the sector in light of the updated Urban Wastewater Treatment Directive (UWWTD). BPCI members successfully reduced Chemical Oxygen Demand (COD) in wastewater by 13% and phosphorus releases by 17.5%, demonstrating proactive alignment with evolving EU zero-pollution frameworks.
Michael Kilkelly, Senior Executive for Environmental, Health and Safety at BPCI, noted:
"This year's data showcases how a decade of technical rigour is paying dividends on the ground. Our emissions to air and water are decreasing despite increased economic growth. We are achieving a record 88% recycling rate and a 30.5% drop in electricity-related CO2 reflecting an immense operational focus from our EHS teams.
We do have challenges around reducing hazardous waste streams that are driven mainly by an increase in complex API production. However, there is a great opportunity here to leverage the collective intelligence of our BPCI network to reduce our use of resources and to recycle our waste streams into the circular economy.”
To read the full findings and learn more about the industry’s strategic sustainability pillars, the Sustainability and Responsible Care Report 2026 is available to download here: https://www.ibec.ie/BPCI_Responsible_Care
ENDS
About BioPharmaChem Ireland BioPharmaChem Ireland (BPCI) represents over 80 pharmaceutical, biopharmaceutical, and chemical manufacturing and services operations in Ireland, and is part of Ibec. BPCI works to support and represent the sector by uniting industry, government, research, and the public to highlight Ireland as a prime location for pharmaceutical development and supply. The sector currently employs 50,000 professionals and generates €116 billion in annual exports, making Ireland the world's third-largest exporter of pharmaceuticals.
